942318-15-2

Upstream product

• 1589-82-8 phenylmagnesium bromide 
• 180748-31-6 1-(4-chloropyridin-2-yl)-2-phenylethan-1-amine 
• 872459-77-3 1-(4-chloropyridin-2-yl)-2-phenylethan-1-one 
• 942318-13-0 tert-butyl N-[-1-(4-chloropyridin-2-yl)-2-phenylethyl]carbamate 
• 942318-14-1 tert-butyl N-[(1S)-1-(4-chloropyridin-2-yl)-2-phenylethyl]carbamate 
• 24484-93-3 4-Chloro-pyridine-2-carboxylic acid methyl ester 
• 942318-16-3 tert-butyl N-[(1S)-1-(4-{4-[(methoxycarbonyl)amino]phenyl}pyridin-2-yl)-2-phenylethyl]carbamate 

Relevant academic research and scientific papers

Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group

Pyridine-based Factor XIa (FXIa) inhibitor (S)-2 was optimized by modifying the P2 prime, P1, and scaffold regions. This work resulted in the discovery of the methyl N-phenyl carbamate P2 prime group which maintained FXIa activity, reduced the number of H

ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS

The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.